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To classify, summarize, and compare the
health economic guidelines (HE) issued in Europe,
North America, and Australia to clarify similarities and
differences between them.
 
Materials and Methods: 
 
In a literature review HE
guidelines were classified according to whether they
were 1) formalized, 2) informal, or 3) guidelines for
health economic methods. All the guidelines were sum-
marized in a table format according to 15 important
methodological aspects. The aspects were compared




A total of 25 guidelines were identified, seven
formalized, eight informal, and 10 guidelines for HE
methods. The levels of agreement for methodological
aspects within groups were 40% to 100%, 25% to
100% and 30% to 100% for the formalized, informal,
and HE guidelines, respectively. The formal guidelines
were slightly more homogenous than the other groups.
The between-group comparison showed that the guide-
lines were in agreement for about 75% of methodologi-
cal aspects. Disagreement between guidelines was found
in choice of perspective, resources, and costs that should





A harmonization of methodological re-
quirements and recommendations exists both within
and between the guideline groups. This review provides
information concerning the core of agreements that
have been reached. A number of policy implications for










In 1992, Australia became the first country to for-
malize and issue mandatory guidelines for health
economic evaluations of pharmaceutical products
as a requirement prior to reimbursement [1]. This
document was revised in 1995 [2]. There are simi-
lar mandatory guidelines in Canada [3], Finland
[4], the Netherlands [5], and Portugal [6], as well
as from the managed care organization Regence
Blue Shield (USA) [7–9]. The newly established
National Institute for Clinical Excellence (NICE)
has just issued its guidelines [10]. The function of
NICE is to appraise the clinical and economic ben-
efits of new and existing technologies in England
and Wales notified by the Department of Health
and the Assembly of Wales, and to make recom-
mendations to the National Health System (NHS).
The impact of NICE is predicted to be significant
because they have strongly promoted implement-
ing and disseminating their recommendations. In
this respect, their guidelines can be regarded as
mandatory. Other countries that have developed
principles and recommendations for use in health
economic evaluations are Denmark [11], Ireland
[12], New Zealand [13], Norway [14], the United
States [15–17], and Switzerland [18], but these
guidelines are still voluntary.
The primary role of guidelines is to function as
input in the pricing and reimbursement process.
Therefore, payers have an interest in scientifically
consistent studies. To clarify what is really required
in undertaking economic evaluations of medical
technologies, research teams around the world have
developed methodological principles and guidelines
for health economic analyses [19–29].
The objective of this review is to: 1) classify, pre-
sent, and group guidelines issued in Europe, North
America, and Australia according to their pur-
pose; 2) provide a comprehensive and structured
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group-wise summary of the guidelines; and 3) gen-
eralize and compare the guidelines according to the
classifications given in 1), to clarify both similarities
and differences between them. Possible policy im-




This review is based on literature from various
sources, such as health economic journals and
government-issued documents. Guidelines issued
by governments were identified by Internet searches;
both directly via the web sites of various authori-
ties and indirectly via the search engine AltaVista,
as well as via direct contacts with the regulatory
authorities. Guidelines published in health eco-
nomic journals were identified both by a literature
search via websites (e.g., PharmacoEconomics:
HTTP://www.adis.com; newsletters) and via Alta-
Vista (search profile: authors, cost-effectiveness, cost-




Guidelines for health economic evaluations have
been classified according to their purpose by Drum-
mond [30]. Drummond outlines three purposes of
guidelines: 1) as a requirement prior to reimburse-
ment 2) as a statement of methodological standards,
and 3) as a statement of ethical standards. In this re-
port we have used Drummond’s first two purposes
or classifications. Good and transparent methodol-
ogy, and justification for assumptions made in eval-
uations, will function to some extent as protection
against the unethical conduct of studies. We have
therefore disregarded the third classification.
Drummond’s first classification was subdivided
into two subgroups: formalized (i.e., mandatory)
requirements prior to reimbursement, and infor-
mal (i.e., voluntary) requirements prior to reim-
bursement. The first subgroup consists of national
guidelines that have been established to control
expenditure for health care technologies and en-
sure that funds are spent in the best possible way.
The second subgroup consists of guidelines that
thus far need not be followed as a part of the reim-
bursement process (although health economic data
may help).
Based on these definitions, we have used the
following classification: formalized guidelines [2–10]
(as a requirement prior to reimbursement), infor-
mal guidelines [11–18] (a recommendation prior
to reimbursement), and guidelines for health eco-
nomic methods [19–29] (guidelines intended for use
in discussing and improving methodology in health
economic evaluations). These three groups of classi-
fications will be used when presenting and compar-
ing the guidelines.
The guidelines are presented in table format,
both individually and by group, under the headings
Background, Methodological Issues and Assistance/
Extra Input. The Background section presents the
affiliation of authors, year of last revision, year of
implementation, purpose, and the target audience.
The next section presents some important method-
ological aspects that researchers ought to keep in
mind when conducting health economic evalua-
tions. The issues in the methodological section orig-
inate from the theoretical framework described in
classical health economic textbooks [31,32] and are
presented in the following order: perspective, re-
source use/costs, outcome measurement, type of
analysis, incremental or average cost-effectiveness,
treatment comparator, methods of data capture,
modeling, time horizon, discounting, sensitivity anal-
ysis, reporting results, and financial implication for
society. The last section, Assistance/Extra Input, re-
ports whether there are standardized price lists when
estimating costs, and if templates are available when
compiling results.
In earlier research related to health economic
guidelines, other dimensions or aspects have also
been considered, e.g., Luce and Simpson [33] dis-
cussed meta-analysis and DeVries and Gagnon
[34] discussed the issue of when studies should be
performed and by whom. Our approach considers
cross-sectional variations in health economic guide-
lines from the perspective of economic theory. Con-
sequently, we do not cover all the interesting and
relevant aspects in the intersection between health
economics and other aspects of importance for the




A Tabulated Summary Of Classified Guidelines
 
A structured summary of the guidelines is pre-
sented in Table 1. The guidelines are presented in
the following order: formalized guidelines A–G
(Table 1a), informal guidelines H–O (Table 1b),
guidelines intended to improve health economic
studies P–Y (Table 1c).
 
A Generalized Comparison of Different Groups
Of Guidelines
 
Table 2 is intended to give a general overview of
the groups of guidelines and their recommenda-
tions, as presented in the previous section. As can
be seen, each group has its own column in the ta-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ble. These columns show the typical guideline
within each cluster at each analytical level. A gen-
eralization has different levels of strength. If all
the guidelines within a group agree about a rec-













 1). When there is
major disagreement between guidelines and more
than half of the guidelines have recommendations
other than the typical example, the level of
strength is marked as vague.
The following one-to-one comparison between
groups has been made: 1) formalized versus infor-
mal, 2) formalized versus health economic meth-
ods, and 3) informal versus health economic meth-
ods. To be as concise as possible, the focus is on
the most obvious differences between the groups.
 
Formalized Guidelines versus Informal Guidelines
 
When the formalized guidelines are compared
with the informal guidelines, it is seen that 12 out
of 15 levels are fairly similar. The most obvious
differences concern 1) the resources/costs that
should be included in the evaluation, 2) the choice
of discount rate, and 3) the valuation of costs.
The formalized guidelines are quite clear on
which costs to include in the health economic
evaluation. Five out of seven stress that all rele-
vant direct health care costs should be included in
the evaluation, while four out of seven of the in-
formal guidelines recommend that the analyst in-
clude all relevant costs, including indirect costs.
Individual time preferences are reflected in the
discount rate. The standard discount rate is 5%
and is often used in health economic evaluations.
The formalized guidelines have adopted this rate
in four out of seven cases. Recommendations in
the informal guidelines are vague; two out of eight
recommend that the analyst adopt a discount rate
between 2.5 and 10%.
The final and perhaps most important differ-
ence between these groups concerns how to mea-
sure costs. The formalized guidelines are divided
into two groups of equal size; three out of seven
suggest country-specific costing, and three out of
seven can provide researchers with price lists.
Whether country-specific costing means that costs
should reflect the best use of resources (opportu-
nity cost) is not obvious. The informal guidelines
are also divided into two groups of equal size; two
out of eight suggest no principles of valuation, or
fees and tariffs, respectively. There seems to be
major disagreement among the informal guide-














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ple, Norway advocates opportunity costing whereas
Switzerland advocates fees and tariffs.
In summary, the formalized guidelines are gener-
ally more homogenous than the informal guidelines.
 
Formalized Guidelines versus Guidelines for Health 
Economic Methods
 
When examining the differences between the for-
malized guidelines and the guidelines for health
economic methods, it is important that their re-
spective purposes be borne in mind. The formal-
ized guidelines were developed to inform decision
makers within the regulatory authority as to whether
a pharmaceutical product adds enough extra value
to be reimbursed. The guidelines for health eco-
nomic methods were established to develop a
state-of-the-art methodology for health economic
evaluation based on economic theory.
The formalized guidelines and the guidelines
for health economic methods are fairly similar in
11 of 15 levels. However, four main differences
can be distinguished between the two types of
guidelines. These are: 1) the perspective of the
evaluation 2) the recommendations and require-
ments concerning evaluation of resource use/costs
3) the choice of treatment comparator, and 4) the
valuation of costs.
The formalized guidelines stress that the perspec-
tive of the analysis should be societal, whereas the
guidelines for health economic methods appear to
be less restrictive. The guidelines for health eco-
nomic methods generally point out that the per-
spective is dependent on the aim of the study. This
means that the researcher has more freedom to
choose the analytical aspects he/she wants to em-
phasize within the scope of the perspective. For ex-
ample, the researcher has the freedom to examine
the impact of two pharmaceutical products on the
utilization of inpatient care and is allowed to ex-
clude costs that fall outside this area. This approach
is narrower than the societal or the health sector
approach. The societal perspective stipulated by the
formalized guidelines does not allow the researcher
to exclude important direct costs within the health
care sector, which include utilization of both inpa-
tient and outpatient care. In this respect the formal-
ized guidelines are more restrictive.
Although the guidelines for health economic
methods are less restrictive in the choice of perspec-
tive, it is interesting to note that these guidelines ac-
tually have more restrictive inclusion criteria con-
cerning resources used and costs. Within the societal
perspective, all costs, both direct and indirect,























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































246 Hjelmgren et al.
pact of a pharmaceutical product. This requirement
is met by the guidelines for health economic meth-
ods but not by the formalized guidelines. Consider-
ation of direct costs outside the health care sector,
such as patients’ out-of-pocket expenses and trans-
portation costs, and indirect costs for productivity
losses, is not a general requirement in the formal-
ized guidelines. The reason for not also including
indirect costs as a requirement could be that the
method (human capital approach) for measuring
these costs is still controversial.
Agreement among the formalized guidelines to
use common practice as the treatment comparator
is quite clear; the strength of this generalization is
five of seven. It is difficult to find a general rule for
choice of comparator in the guidelines for health
economic methods. A variety of different compar-
ators are suggested, such as existing practice, min-
imum practice, and most effective practice, but
these definitions are quite vague. The most general
recommendation is existing practice, which is
stressed in 3 out of 10 cases. If the definitions for
existing practice and common practice are consid-
ered to overlap, there is a weak relationship be-
tween the formalized guidelines and the guidelines
for health economic methods in this area.
Valuation of health care resources appears to
be a difficult problem. A general rule for decision
making in formalized guidelines does not exist—
both country-specific costing and use of available
price lists are recommended—however, the princi-
ple on which valuation of resources rests is un-
clear. In 5 out of 10 cases the guidelines for health
economic methods stress that resources should re-
flect the opportunity cost of the resources used.
This principle is a cornerstone in economics, but it
is difficult to apply in practice because of imper-
fections in health care markets.
In summary, there appears to be more agreement
among regulatory authorities than among health
economic researchers on how to guide those who
perform health economic studies.
Informal Guidelines versus Guidelines for Health 
Economic Methods
When the informal guidelines are compared with
the guidelines for health economic methods, it can
be seen that 11 levels out of 15 are fairly similar.
However, obvious differences are noted in four ar-
eas. These are: 1) the perspective of the study 2)
the choice of treatment comparator 3) the choice
of discount rate, and 4) the valuation of costs. Dif-
ferences in the choice of discount rate and in the
valuation of costs were discussed when we ana-
lyzed formalized versus informal guidelines and
formalized versus health economic methods. We
shall now focus on 1) and 2).
As was already pointed out, the guidelines for
health economic methods have adopted a perspec-
tive that is dependent on the aim of the study. The
informal guidelines have adopted a societal per-
spective in three out of eight cases and a multiple
perspective in two out of eight cases. A logical
explanation for this distribution in the informal
guidelines could be the differences in health care
systems in the countries that have issued these
guidelines. For instance, the US FDA guidelines and
the Swiss guidelines are both informal guidelines.
Both reflect the respective health care systems in
these countries. These health care systems are based
on a free-market structure wherein a variety of pro-
viders and payers of health care coexist as separate
bodies. The private (third-party) payers of health
care, i.e., insurance companies, focus on direct
health care costs that would otherwise be borne by
the patient himself/herself. This means that costs
falling outside this range are more or less ignored
(e.g., costs for workdays lost). On the other hand,
in countries like Norway and Denmark that are
more regulated, the government plays a major role
in governing the health care system; hence, the soci-
etal perspective is of more interest.
As was the case when we compared the formal-
ized guidelines and the guidelines for health eco-
nomic methods, there appears to be some confusion
concerning the definitions of alternative treatments.
The informal guidelines are vague in their recom-
mendations of common practice as the treatment
comparator (3/8), and the guidelines for health
economic methods are vague in their recommen-
dations of existing practice (3/10). Are these
poorly defined concepts equivalent, or do they
partly overlap? If they are equivalent, agreement
between the informal and the health economic
guidelines is weak. If they only partly overlap,
agreement is very weak.
In summary, the informal guidelines and the
guidelines for health economic methods seem to
be equally generalized.
Discussion
This review has classified, summarized, and com-
pared health economic guidelines issued in Eu-
rope, North America, and Australia according to
their purpose. Three classes of guidelines were
identified and compared: formalized guidelines
(i.e., mandatory guidelines prior to reimburse-
Health Economic Guidelines 247
ment), informal guidelines (i.e., voluntary guide-
lines prior to reimbursement), and guidelines in-
tended for use in improving and discussing health
economic methods.
Fairly good agreement could be found in about
three quarters of the guideline recommendations
such as type of analysis (cost-effectiveness analysis
and cost-utility analysis), incremental cost-effec-
tiveness ratios, acceptance of modeling, and ade-
quacy of time horizon. This indicates good har-
monization among the three sets of guidelines
concerning core aspects. One possible explanation
for this harmonization could be that the formal-
ized guidelines were generally issued earlier than
the informal guidelines and therefore could be
functioning as a template.
There are some important differences among
the three groups, however. For instance, disagree-
ment could be found in the perspective of the
study, resources used and costs, and the valuation
of resources used in the analysis. The perspective
of the study and the choice of resources and costs
used vary because of differences in health care sys-
tems or in the purposes of the guidelines. The
monetary valuation of resources and costs used
seems to vary because most guidelines do not have
standardized recommendations for valuation, such
as price lists.
Methodological recommendations concerning
guidelines have been reviewed earlier [33–38].
However, reviews must be updated regularly as
more countries continue to develop guidelines,
and the status of existing and newly issued guide-
lines is ambiguous. In some countries guidelines
are a formal requirement, whereas in others they
are still used on a voluntary basis.
This review contains a substantial number of
health economic guidelines. It is, however, not im-
plausible that we have missed some guidelines, for
example, guidelines published in a non-English
journal. We have also intentionally excluded liter-
ature on health economic evaluation with text-
book approaches [31,32] and guidelines specifi-
cally intended for internal use by an organization.
In addition, some early guidelines have been with-
drawn or are simply outdated.
Guidelines are likely to affect both the produc-
ers and the consumers of economic evaluations.
We will focus here on some aspects that might be
important to address in the interpretation and im-
plementation of guidelines for the parties involved.
Most of the formal guidelines state that their
view is societal, but they nevertheless insist on fo-
cusing primarily on direct health care costs. One
consequence of not recommending that indirect
costs also should be included is that they increase
the potential difficulty of proving the cost-effective-
ness of certain classes of newly developed drugs.
Advantages in aspects of productivity do not bear
the same weight as advantages in the health care
sector. Future research might change this, since in
general economic terms changes in productivity
are constantly in focus, i.e., increases in gross do-
mestic product are usually major news.
The principles for monetary valuation of re-
sources are unclear, or at least not explicit, in most
guidelines. For purposes of comparability, these
need to be harmonized. Harmonization with re-
spect to prices, through the establishment of inde-
pendent databases, is one way to apply an external
standard. Another way is to communicate with
customers (e.g., third-party payers, authorities) a
priori about which prices are appropriate to use.
The comparators in cost-effectiveness analyses
ought to relate to plausible substitutes under nor-
mal practice. However, how to implement this in
multinational clinical trials is not evident, since
normal clinical practices may vary substantially
even within one country. In many cases it may be
difficult to identify the treatments that ought to be
included in a study to fulfill the HE requirements
of many different countries.
Most guidelines demand effectiveness data and
not efficacy data. Effectiveness data demonstrate
that the evaluated treatment works in normal clin-
ical practice, while efficacy data show that the
evaluated treatment has an impact on patients in a
structured setting. The increasing demand for ef-
fectiveness data has considerable impact on the
design of clinical studies, e.g., the number of pa-
tients needed to be able to show a significant dif-
ference between treatments when the patient groups
are somewhat heterogeneous.
Harmonization of outcomes and effectiveness is
essential if studies are to be compared. Recommen-
dations concerning appropriate outcome measures
might be necessary to allow comparison of different
studies with different treatments. One way to in-
crease comparability is through research on patient
preferences for various indications. In economics,
preferences are treated as rather stable, and re-
search on patient preferences concerning different
symptoms might be essential in choosing outcome
and effectiveness measures. In this way, conflicting
messages could be avoided when products for the
same indication are priced or reimbursed.
Economists are not able to discuss with cer-
tainty health-related behavior based on normative
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health economic evaluations. Therefore, decisions
based solely on health economic data prior to
launch of a treatment cannot constitute the only
foundation on which reimbursement decisions are
based. Hutton and Maynard [39] have pointed
out that “the economic result can never be defini-
tive at that stage.” Economic evaluations along-
side closely monitored clinical trials should not be
regarded as the state of the art approach for ap-
praisals post launch. After a drug is launched,
however, the option of analyzing real-life data be-
comes available. The real-life impact of a particu-
lar drug could be assessed by conducting health
econometric analyses, or other kinds of retrospec-
tive analyses on administrative databases. This is
more in line with mainstream economics than the
narrow use of health economics or pharmacoeco-
nomic analyses alongside clinical trials. Alterna-
tively, clinical studies might be replicated with ret-
rospective data from different sorts of databases.
Providing a model has occasionally been the so-
lution when there is a lack of information. Models
are accepted and even required in most countries.
Given the chronic nature of many diseases, it is
reasonable and necessary to conduct research us-
ing long-term models that ought to be developed
over time, expanded, and disseminated. There
might, however, be a trade-off between modeling
research and the implementation of prospective
health economic analyses and health econometric
analyses. In the future, it will be reasonable to ex-
pect the provider of formal guidelines to also pro-
vide guidance on the types of analyses that are ac-
ceptable under different circumstances.
Providing detailed guidelines is cumbersome
work, and if they are provided, they run the risk
of becoming a cookbook instead of a useful tool
for conducting an appraisal. The extent to which
guidelines will become a useful tool for the health
care sector in different countries in working with
issues such as cost-containment and cost-effective-
ness, remains to be seen. There are recent data
suggesting that the studies received so far by the
reimbursement authorities in Australia and the
Canadian province of British Columbia may not
be optimal [40–42]. It is clear from these data that
the pharmaceutical industry needs to work in a
more long-term, strategic, and innovative way to
support its products with useful, timely, and high-
quality health economic data.
Developing guidelines is a dynamic process; the
number of formal health economic guidelines is
increasing, and the content of the guidelines will
most likely be further developed. The develop-
ment of guidelines will hopefully be the result of
the interaction between the interested parties: pa-
tient groups, governments, the industry, third-
party payers, researchers, etc. These parties usually
have conflicting interests. For instance, the reac-
tion of Glaxo Wellcome and the industry toward
the NICE decision to not recommend the flu drug
Relenza as a treatment attracted worldwide atten-
tion. Glaxo Wellcome was said to be considering
taking legal actions if NICE refused to recommend
Relenza, and the company even threatened to
move out of the UK [43,44]. In Canada and Aus-
tralia also, pharmaceutical companies have brought
political and legal pressure on the institutions re-
sponsible for judging the relative merits of their
products [45,46].
From the industry’s point of view it is impor-
tant to take a constructive part in the development
of guidelines and to be given the opportunity to
propose ways of improving these guidelines. If
not, the credibility of the result may be taxed, since
many health economic analyses are presently nor-
mative, or the results can be used normatively as a
result of the experimental setting of the clinical
studies on which they are based.
In conclusion, this review has covered 25 health
economic guidelines, which can be considered as
fairly homogenous. However, there are differences
between guidelines to which pharmaceutical com-
panies should pay attention in an effort to design
studies that are as relevant and acceptable as pos-
sible. Whether or not the guidelines will be an effi-
cient way of regulating the market remains to be
seen. Resources will unavoidably continue to be
limited, however, despite the success or failure of
the guidelines in their present form. If the guide-
lines turn out to be unsatisfactory, other health
policy instruments will most likely replace them.
AstraZeneca R & D Lund, Sweden funded this study.
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